Kazia Therapeutics Limited filed its Annual Report on Form 20-F, outlining continued operating losses and funding needs as it advances oncology programs. The company reported net losses of A$20.5 million, A$26.8 million, and A$20.7 million for fiscal years 2023, 2024, and 2025, respectively. Revenue was A$42 thousand in 2025, compared with A$2.3 million in 2024, reflecting the irregular nature of licensing income.
As of June 30, 2025, cash at bank was A$4.3 million, and the company raised A$16 million during the year from ADS sales. Management disclosed substantial doubt about the company’s ability to continue as a going concern, with current resources expected to fund operations until approximately March 2026. The “Baby Shelf Rule” limits capital raises under Form F-3 until non‑affiliate float exceeds $75 million. Ordinary shares outstanding were 809,418,734 as of June 30, 2025.
Kazia completed ADS ratio changes, moving to 1 ADS = 100 ordinary shares on October 28, 2024 and to 1 ADS = 500 ordinary shares on April 17, 2025. Lead programs include paxalisib (PI3K/Akt/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor), with added pipeline work through collaborations with QIMR, including a PD‑L1 degrader program.
Kazia Therapeutics announced an in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 protein degrader program centered on lead compound NDL2. The company expects IND-enabling studies to start within six months and aims to begin first-in-human studies in approximately 15 months. Kazia will make a $1.39M one-time payment within 15 business days after signing and will be responsible for development costs. If commercialized, Kazia will receive a percentage of commercialization revenue in the mid-to-high double digits, including out-licensing receipts. The announcement notes these are forward-looking goals and Kazia has no obligation to update such statements except as required by law.
Kazia Therapeutics Limited filed a Form 6-K to furnish a press release describing an 86% reduction in tumor burden in an expanded-access case of a metastatic triple-negative breast cancer (TNBC) patient treated with a paxalisib-immunotherapy regimen. The press release, dated October 2, 2025, is attached as Exhibit 99.1.
The company is also incorporating the information in this report, including Exhibit 99.1 but excluding the quoted remarks from its Chief Executive Officer, into its existing Form F-3 registration statement (File No. 333-281937). This links the clinical case update to the company’s broader capital-raising framework.
Kazia Therapeutics Ltd: This Schedule 13G/A discloses that Alumni Capital LP, Alumni Capital GP LLC and Ashkan Mapar are collectively reported as beneficially owning 178,591 American Depository Shares (ADSs), representing 9.99% of the class on the filing’s stated basis. The reported percentage is calculated using the issuer's representation of 1,609,108 ADSs outstanding and reflects an Ownership Limitation that prevents the Fund from acquiring ADSs that would raise ownership above 9.99%.
The filing clarifies that the Fund actually owns 28,409 ADSs as of the filing date but may be deemed to beneficially own additional ADSs pursuant to a Purchase Agreement (dated April 19, 2024), Commitment Warrants, Common Warrants (dated January 10, 2025) and a July 31, 2025 Securities Purchase Agreement. All three Reporting Persons share voting and dispositive power over the 178,591 ADSs. Signatures are dated 09/11/2025.
Kazia Therapeutics Limited submitted a Form 6-K to provide investors with a new press release about its cancer drug candidate paxalisib. The release, dated September 11, 2025, is titled “Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy.” The filing makes this press release publicly available as Exhibit 99.1 and incorporates its information, other than a quote from the Chief Executive Officer, into Kazia’s existing Form F-3 registration statement, which may be used for future securities offerings.
Kazia Therapeutics Ltd filed a Form D reporting a Regulation D, Rule 506(b) offering that raised $2,050,013, with $2,050,013 sold and $0 remaining. The filing lists four investors and identifies offered securities as equity, options/warrants, and securities issuable on exercise.
The notice discloses pre-funded warrants to purchase up to 204,547 ADSs, each ADS representing 500 ordinary shares, and each pre-funded warrant exercisable for one ADS at an exercise price of $0.0001 per ADS. The filing reports $0 in sales commissions and finders' fees, $0 of proceeds paid to named officers or directors, and was signed by CEO John Friend on 2025-08-14.
On 31 Jul 2025 Kazia Therapeutics (KZIA) entered a definitive agreement for a private placement expected to close on or about 4 Aug 2025. Investors will buy 14,204,500 ordinary shares at US$0.0176 per share and pre-funded warrants exercisable for up to 204,547 ADSs (1 ADS = 500 shares) at US$8.7999 per warrant, with a token exercise price of US$0.0001 per ADS. Warrant holders are limited to 9.99 % beneficial ownership unless they give 61-day notice to increase the cap.
The transaction should yield ~US$2 million net proceeds after expenses. Kazia intends to direct the funds toward ongoing clinical development of paxalisib (brain-penetrant PI3K/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor) and for general corporate purposes. The securities were issued under Section 4(a)(2) and Rule 506 exemptions; Kazia must file a resale registration statement within 60 days of closing and keep it effective until investors no longer hold the securities.
No financial results or guidance were provided. Closing remains subject to customary conditions.